daddy-kool wrote: ↑17/09/2021 10:01
Stavi link na bar jedan.
Although stage I and II of the clinical trials are
modest, stage III is a much bigger phase requiring a huge cohort in each investigational
setting. Whether the lead is safe or not is assessed in stage I trials, while stage II is reserved
for determining efficacy. The efficacy and safety are assessed on a much bigger scale in
stage III clinical trials, after which the regulatory bodies decide whether to approve or reject
the vaccine candidate. Although the hastening of this whole cycle might be attributable
to the seriousness of the COVID-19 pandemic, efficacy and safety should not, and were
not, undermined at any stage. Even after guidelines are changed to speed up the vaccine
production, it was still unrealistic to anticipate the development of safe and efficacious
vaccine inside a half year after the beginning of clinical trials. Further difficulties might be
confronted after a vaccine is approved for general use, particularly manufacturing at the
scale to vaccinate the entire world population. This would be more probable if increasing
the production includes new technologies that have not been tested beforehand.
https://www.mdpi.com › pdfPDF
Web results
Vaccine Development against COVID-19: Study from Pre-Clinical Phases to Clinical Trials and Global Use - MDPI
https://www.mdpi.com/journal/vaccinesrezultate dobili na cak 78 ispitanika i hopa, vakcinisi sve sto mozes. Iste ili slicne brojke su i kod ostalih, stotinu, dvjesto, tristo ljudi, zastita 70% - 80% - 90%
i daj da vakcinisemo milijarde ljudi, vjerujte nam na rijec varijanta. Ima logike, realno
